DCTH Quote, Financials, Valuation and Earnings

Exact Sciences has a net margin of -22.5% compared to Delcath Systems's net margin of -121.19%. Delcath Systems's return on equity of -117.89% beat Exact Sciences's return on equity of -34.11%.

Delcath Systems has a consensus price target of $22.50, signalling upside risk potential of 68.79%. On the other hand Exact Sciences has an analysts' consensus of $69.43 which suggests that it could grow by 54.56%. Given that Delcath Systems has higher upside potential than Exact Sciences, analysts believe Delcath Systems is more attractive than Exact Sciences.

Delcath Systems has a beta of 0.820, which suggesting that the stock is 17.957% less volatile than S&P 500. In comparison Exact Sciences has a beta of 1.248, suggesting its more volatile than the S&P 500 by 24.844%.

Delcath Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Delcath Systems pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Delcath Systems quarterly revenues are $15.1M, which are smaller than Exact Sciences quarterly revenues of $713.4M. Delcath Systems's net income of -$3.4M is higher than Exact Sciences's net income of -$864.6M. Notably, Delcath Systems's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems is 10.54x versus 3.00x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Neuronetics has a net margin of -22.5% compared to Delcath Systems's net margin of -54.05%. Delcath Systems's return on equity of -117.89% beat Neuronetics's return on equity of -188.28%.

Delcath Systems has a consensus price target of $22.50, signalling upside risk potential of 68.79%. On the other hand Neuronetics has an analysts' consensus of $6.83 which suggests that it could grow by 67.48%. Given that Delcath Systems has higher upside potential than Neuronetics, analysts believe Delcath Systems is more attractive than Neuronetics.

Delcath Systems has a beta of 0.820, which suggesting that the stock is 17.957% less volatile than S&P 500. In comparison Neuronetics has a beta of 2.072, suggesting its more volatile than the S&P 500 by 107.234%.

Delcath Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neuronetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Delcath Systems pays -- of its earnings as a dividend. Neuronetics pays out -- of its earnings as a dividend.

Delcath Systems quarterly revenues are $15.1M, which are smaller than Neuronetics quarterly revenues of $22.5M. Delcath Systems's net income of -$3.4M is higher than Neuronetics's net income of -$12.2M. Notably, Delcath Systems's price-to-earnings ratio is -- while Neuronetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems is 10.54x versus 1.72x for Neuronetics. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -22.5% compared to Delcath Systems's net margin of -14.37%. Delcath Systems's return on equity of -117.89% beat Star Equity Holdings's return on equity of -17.45%.

Delcath Systems has a consensus price target of $22.50, signalling upside risk potential of 68.79%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 284.63%. Given that Star Equity Holdings has higher upside potential than Delcath Systems, analysts believe Star Equity Holdings is more attractive than Delcath Systems.

Delcath Systems has a beta of 0.820, which suggesting that the stock is 17.957% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.075, suggesting its less volatile than the S&P 500 by 92.536%.

Delcath Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Delcath Systems pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Delcath Systems quarterly revenues are $15.1M, which are smaller than Star Equity Holdings quarterly revenues of $17.1M. Delcath Systems's net income of -$3.4M is lower than Star Equity Holdings's net income of -$2.5M. Notably, Delcath Systems's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems is 10.54x versus 0.15x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.

GeneDx Holdings has a net margin of -22.5% compared to Delcath Systems's net margin of 5.69%. Delcath Systems's return on equity of -117.89% beat GeneDx Holdings's return on equity of -24.23%.

Delcath Systems has a consensus price target of $22.50, signalling upside risk potential of 68.79%. On the other hand GeneDx Holdings has an analysts' consensus of $107.33 which suggests that it could grow by 11.3%. Given that Delcath Systems has higher upside potential than GeneDx Holdings, analysts believe Delcath Systems is more attractive than GeneDx Holdings.

Delcath Systems has a beta of 0.820, which suggesting that the stock is 17.957% less volatile than S&P 500. In comparison GeneDx Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Delcath Systems has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeneDx Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Delcath Systems pays -- of its earnings as a dividend. GeneDx Holdings pays out -- of its earnings as a dividend.

Delcath Systems quarterly revenues are $15.1M, which are smaller than GeneDx Holdings quarterly revenues of $95.6M. Delcath Systems's net income of -$3.4M is lower than GeneDx Holdings's net income of $5.4M. Notably, Delcath Systems's price-to-earnings ratio is -- while GeneDx Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Delcath Systems is 10.54x versus 8.49x for GeneDx Holdings. Usually stocks with elevated PS ratios are considered overvalued.